Zobrazeno 1 - 10
of 109
pro vyhledávání: '"Wim G Goettsch"'
Autor:
Aukje K Mantel-Teeuwisse, Rick A Vreman, Olaf H Klungel, Junfeng Wang, Li Jiu, Michiel Hartog, Wim G Goettsch
Publikováno v:
BMJ Open, Vol 14, Iss 2 (2024)
Objectives We aimed to identify existing appraisal tools for non-randomised studies of interventions (NRSIs) and to compare the criteria that the tools provide at the quality-item level.Design Literature review through three approaches: systematic se
Externí odkaz:
https://doaj.org/article/eca10fb6c00541ad97d8d3bec20823d7
Publikováno v:
Journal of Medical Internet Research, Vol 23, Iss 12, p e27497 (2021)
BackgroundThere is a general agreement on the importance of health-related quality of life (HRQoL). This type of information is becoming increasingly important for the value assessment of health technology assessment agencies in evaluating the benefi
Externí odkaz:
https://doaj.org/article/c38a5cc94913450b8b3822ee3917b3d9
Autor:
Daphne H. Schoenmakers, Shanice Beerepoot, Sibren van den Berg, Laura Adang, Annette Bley, Jaap-Jan Boelens, Francesca Fumagalli, Wim G. Goettsch, Sabine Grønborg, Samuel Groeschel, Peter M. van Hasselt, Carla E. M. Hollak, Caroline Lindemans, Fanny Mochel, Peter G. M. Mol, Caroline Sevin, Ayelet Zerem, Ludger Schöls, Nicole I. Wolf
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 17, Iss 1, Pp 1-14 (2022)
Abstract Background Metachromatic Leukodystrophy (MLD) is a rare lysosomal disorder. Patients suffer from relentless neurological deterioration leading to premature death. Recently, new treatment modalities, including gene therapy and enzyme replacem
Externí odkaz:
https://doaj.org/article/8c393f5208e146328f0af2066de15352
Autor:
Yoon Duk Hong, Jeroen P. Jansen, John Guerino, Marc L. Berger, William Crown, Wim G. Goettsch, C. Daniel Mullins, Richard J. Willke, Lucinda S. Orsini
Publikováno v:
BMC Medicine, Vol 19, Iss 1, Pp 1-15 (2021)
Abstract Background There have been ongoing efforts to understand when and how data from observational studies can be applied to clinical and regulatory decision making. The objective of this review was to assess the comparability of relative treatme
Externí odkaz:
https://doaj.org/article/d0edb6fd6683440782ff5b49f776769c
Autor:
Ildikó Ádám, Marcelien Callenbach, Bertalan Németh, Rick A. Vreman, Cecilia Tollin, Johan Pontén, Dalia Dawoud, Jamie Elvidge, Nick Crabb, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Anke Pisters-van Roy, Áron Vincziczki, Emad Almomani, Maja Vajagic, Z. Gulsen Oner, Mirna Matni, Jurij Fürst, Rabia Kahveci, Wim G. Goettsch, Zoltán Kaló
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Outcome-based reimbursement models can effectively reduce the financial risk to health care payers in cases when there is important uncertainty or heterogeneity regarding the clinical value of health technologies. Still, health care payers in lower i
Externí odkaz:
https://doaj.org/article/cad946d469d047ba9bcf6c3dcb92c059
Autor:
Lourens T. Bloem, Rick A. Vreman, Niels W. L. Peeters, Jarno Hoekman, Menno E. van derElst, Hubert G. M. Leufkens, Olaf H. Klungel, Wim G. Goettsch, Aukje K. Mantel‐Teeuwisse
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 4, Pp 1566-1577 (2021)
Abstract We aimed to determine whether uncertainties identified by the European Medicines Agency (EMA) were associated with negative relative effectiveness assessments (REAs) and negative overall reimbursement recommendations by national health techn
Externí odkaz:
https://doaj.org/article/a2e8481c77804dc8b050c8e96f840417
Autor:
Ildikó Ádám, Marcelien Callenbach, Bertalan Németh, Rick A. Vreman, Johan Pontén, Tea Strbad, Dalia Dawoud, Alexander Kostyuk, Ahmed Seyam, László Nagy, Wim G. Goettsch, Zoltán Kaló
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
The need for innovative payment models for health technologies with high upfront costs has emerged due to affordability concerns across the world. Early technology adopter countries have been experimenting with delayed payment schemes. Our objective
Externí odkaz:
https://doaj.org/article/0b19785b0d4d47f0ba93c49a8b790e2b
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: The target product profile (TPP) outlines the desired profile of a target product aimed at a particular disease and is used by companies to plan clinical development. Considering the increasing importance of health technology assessment (
Externí odkaz:
https://doaj.org/article/d25677fa677b4d608b735843d9929e4a
Autor:
Milou A. Hogervorst, Johan Pontén, Rick A. Vreman, Aukje K. Mantel-Teeuwisse, Wim G. Goettsch
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
The available evidence on relative effectiveness and risks of new health technologies is often limited at the time of health technology assessment (HTA). Additionally, a wide variety in real-world data (RWD) policies exist among HTA organizations. Th
Externí odkaz:
https://doaj.org/article/caac2b43de694bdfa092c450cebdc2da
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 2, Pp n/a-n/a (2021)
Abstract Standard outcome sets developed by the International Consortium for Health Outcomes Measurement (ICHOM) facilitate value‐based health care in healthcare practice and have gained traction from regulators and Health Technology Assessment (HT
Externí odkaz:
https://doaj.org/article/10a95d6758f14989b133b175bf2f686a